Peptides for healing
Also called: healing peptides
Clinical reviewer: Jacob Moore, MD · Last checked September 22, 2026
Which peptides help with injury healing?
Peptides for healing refers to peptides marketed for tissue repair and recovery, most often BPC-157, TB-500, GHK-Cu and KPV, none of which is FDA-approved for that use. A 2026 review calls BPC-157's human findings "largely unvalidated" and finds no human orthopaedic data for TB-500. An FDA advisory committee recommended several of these peptides in July 2026, a non-binding vote.
Which peptides are marketed for injury healing?
A 2026 review of injectable peptides found "BPC-157 demonstrated potential benefits in tendon and muscle repair, but these findings are largely unvalidated in human trials," with one small case series of knee injections limited by "significant methodological flaws and a lack of controls" [1]. The same review found "TB-4 and its derivative TB-500 promoted angiogenesis and tissue repair in preclinical models, but human orthopaedic data are lacking" [1], and that "GHK-Cu showed promise in wound healing and anti-inflammatory effects, but no clinical data support its use for musculoskeletal conditions" [1].
What is each peptide's FDA status?
None is FDA-approved for healing or any other use. FDA's Category 2 list records BPC-157, TB-500 and KPV's compounding nominations as withdrawn, and separately records injectable GHK-Cu's nomination as withdrawn [2]. For KPV, FDA reviewed a nomination citing nine literature references and found "none were studies of KPV administered in humans" [3].
What happened at the July 2026 advisory committee vote?
FDA's Pharmacy Compounding Advisory Committee voted 8 to 6, with one abstention, on July 23, 2026 to recommend allowing BPC-157, KPV and TB-500 to be compounded, in one combined vote [4]. The vote is non-binding, and FDA has not added any of these peptides to the 503A bulks list.
Related terms
Sources
- Mayfield CK et al. Injectable Peptide Therapy, A Primer for Orthopaedic and Sports Medicine Physicians. Am J Sports Med, 2026.
- FDA — Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks (Category 2), current as of April 22, 2026
- FDA Briefing Document — Pharmacy Compounding Advisory Committee Meeting, July 23-24, 2026 (KPV)
- Pharmaceutical Executive — FDA Panel Votes to Loosen Restrictions for Four Peptides (July 24, 2026)
This entry is for education and is not medical advice. Talk with a licensed clinician about your own situation before starting, stopping, or changing any treatment.
